News

This Phase IIa, double-blind, placebo-controlled study will enroll up to 150 subjects with type 2 diabetes who are currently being treated with basal insulin and oral anti-diabetes agents.

The sites are Florida Hospital/Cardiovascular Institute – Orlando Florida and Chandler Regional Medical Center and Mercy Gilbert Medical Center – Phoenix Arizona metropolitan area. Mercy Hospital Fairfield (Ohio)

According to Gentronix, GreenScreen HC is the first human cell based assay technology that combines high sensitivity for detecting genotoxic chemicals with high specificity for reducing false positive

IC14 is a clinical stage recombinant chimeric monoclonal antibody which recognizes and blocks the function of human CD14, an essential component of the innate inflammatory response to bacterial

Glufast, originally created and developed by Kissei, co-marketed in tandem with Takeda in Japan since May 2004, is a diabetic medicine that promotes insulin secretion by stimulating the

Medipattern has recently signed an agreement with GE Healthcare to create a set of image quantification tools to help physicians visualize plaque and other conditions that can block

Upon approval of Pluristem’s investigational new drug and investigational medicinal product dossier submissions in the US and Europe, Pluristem plans to initiate Phase I clinical trials by administering

Financial highlights Research and development expenses Research and development expenses increased to AUD11,585,258 in 2008 from AUD7,157,216 in 2007. General and administrative expenses General and administrative expenses increased

In this new role, Vertatschitsch will oversee all engineering, clinical, information technology and manufacturing operations Jed Palmacci has widespread experience building and managing global sales organizations within successful